Answers are grounded in this paper and cite their sources.
Background: Early pandemic reports suggested improved outcomes in hypertensive COVID-19 patients treated with angiotensin-converting enzyme inhibitors (ACEI) or amantadine. This study evaluates their impact on disease progression. Methods: We analyzed 55,936 infected patients (March 2020–January 2025) and 2024 hospital admissions within a free-access Barcelona metropolitan health consortium (n = 192,651 as of March 2025). Hospitalizations, stratified by polypharmacy level (nT), were compared via Chi-square tests. ICU admissions and length of stay in hospitalized patients were assessed during the first month of key waves: initial A2a + B3a + B9 (n = 184, March 2020), Delta (n = 158, July 2021), Omicron21K (n = 142, January 2022), and Omicron 24F (n = 8, January 2025). Results: Non-survivors were predominantly aged >60 years (96.3%) in the first wave and >70 years (100%) in Delta/Omicron waves. Post-vaccination, mortality decreased in high-comorbidity groups, though hospitalizations/ICU admissions in younger patients surpassed first-wave levels during Delta. Vaccinated ACEI/ARB-treated patients showed reduced hospitalizations across all polypharmacy groups: OR (noACEI/ACEI) = 1.21 (≥2 nT) to 4.26 (1 nT, p = 0.014); OR (noARB/ARB) = 1.24 (≥8 nT) to 1.74 (2–7 nT, p = 0.01). No hospitalizations occurred in amantadine-treated patients aged <70. Conclusions: These findings suggest a potential protective effect of ACEI, ARBs, and amantadine against severe COVID-19 and support the safety and continuity of these treatments. Multicentric studies incorporating post-COVID syndrome data are needed to validate these observations if hospitalizations persist.
No takes yet. Share an insight, caveat, or question.
Puigdellívol‐Sánchez et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: